Insights & Resources

Texas life sciences in 2025 saw concentrated capital, declining innovation output and earlier‑stage clinical shifts shaping the ecosystem.

Get ahead of the curve by looking back at emerging trends in 2025 that are likely to impact health care valuation in 2026 and beyond. Download Weaver Insights now.

Texas life sciences saw record capital in Q4 2025, even as innovation, early-stage funding and late-phase clinical trials continued to decline.

PET, CT and MRI volumes are accelerating. Learn what uneven imaging growth means for valuation and long-term planning.

Growth strategies in behavioral health are shifting. Learn how leaders can respond to industry headwinds and optimize performance effectively.

Key SEC 2026 exam priorities for RIAs and private funds, including fiduciary duty, AI oversight, cybersecurity and compliance expectations.

AI-driven growth, SEC reforms and shifting investor sentiment shaped Q3 2025. Weaver’s asset management team highlights key trends and risks.

Explore common pitfalls in management company accounting, from consolidation and revenue recognition to leases and alternatives to a U.S. GAAP audit.

Premarital and LLC agreements can override statutory defaults in divorce valuations. The In re S.R.W. case shows how they reshape economic interests.

Explore Q3 2025 trends in Texas life sciences, from Series B collapse and pipeline bottlenecks to sector divergence and record late-stage capital.

Learn why ESOP audits matter, common pitfalls to avoid and how proactive communication and valuation reviews can strengthen plan integrity.

Costs are climbing across health care supply chains. Learn which areas face the most pressure and how to plan with confidence.